BioSpace News Archive

FDA

Merck Wins Key FDA Approval for Pediatric Pneumococcal Vaccine

On Wednesday, the FDA approved Merck’s pneumococcal 15-valent conjugate vaccine for children 6 weeks through 17 years of age.

June 22, 2022
·
2 min read
·
Hannah Chudleigh
Career Advice

What Employers Really Look For in Medical Sales Candidates

BioSpace spoke with Jay Johnson, the Director of Talent Acquisition for Orthopedics at Stryker, to find out what it takes to land a job in medical sales.

June 22, 2022
·
2 min read
·
Franklin Carpenter
Global Roundup: Olink Publishes Updated Genetic Atlas of the Plasma Proteome

Olink said the measurement of proteins at “population scale” provides the ability to improve the understanding of underlying mechanisms of diseases.

June 22, 2022
·
5 min read
·
Alex Keown
Drug Development

PhaseBio’s Reversal Agent for Astra’s Brilinta could Spell Success for Both

PhaseBio is working toward mitigating the surgical risks for cardiac patients taking antiplatelet therapies with bentracimab, which is currently in Phase III development.

June 22, 2022
·
4 min read
·
Gail Dutton
Job Trends

NYC Life Sciences Sector Poised for High-Growth Phase

According to a recent report, the New York City Metro area is home to 7% of the U.S. population but contains 10% of all U.S. biochemists and biophysicists and 12% of U.S. chemists.

June 22, 2022
·
4 min read
·
Alex Keown
Policy

Novartis Loses Upper Hand In Patent Dispute Over $2.7B MS Drug

Novartis’ win in the patent dispute over its drug, Gilenya, was short-lived after a U.S. appeals court reversed its 2020 ruling vs. HEC Pharm’s attempt to create a generic version.

June 22, 2022
·
2 min read
·
Vanessa Doctor, RN
Policy

Bipartisan Senate Bill Aims to Lower Insulin Costs

The bill would curb the pricing of insulin by capping monthly co-pays for diabetics who use both commercial insurance plans, as well as the government-backed Medicare.

June 22, 2022
·
3 min read
·
Alex Keown
Policy

Krystal Biotech Submits BLA for Rare Skin Disease Treatment

Krystal Biotech announced that it submitted a Biologics License Application to the FDA for its candidate B-VEC, intended for the treatment of dystrophic epidermolysis bullosa.

June 22, 2022
·
2 min read
·
Hayley Shasteen
Business

Money on the Move: Scholar Rock, Alladapt, Carbon, Elucid and More

Funding for life sciences companies picked up this week as investors pumped new money into firms developing treatments for spinal muscular atrophy (SMA), immuno-oncology, allergies and rare diseases.

June 22, 2022
·
4 min read
·
Hannah Chudleigh
Drug Development

Athira Puts Optimistic Subgroup Spin on Failed Alzheimer’s Trial

Athira Pharma is putting a positive spin on its topline data from a Phase II trial of fosgonimeton, emphasizing positive subgroup analysis, but it missed the primary endpoint.

June 22, 2022
·
3 min read
·
Mark Terry